Massachusetts is currently home to 3159 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Neuroblastoma Maintenance Therapy Trial
NCT02679144
Recruiting
Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
09/18/2024
Locations: Tufts Medical Center, Boston, Massachusetts
Conditions: Neuroblastoma
Register for Updates
tRNS Treatment for ADHD Symptoms
NCT06189703
Recruiting
A randomized, sham-controlled, double-blind clinical trial to examine the safety and effectiveness of tRNS on unmedicated pediatric patients (7-12 years) with ADHD. Subjects will undergo either tRNS or sham treatment for 10 days during a two-week period in a home-simulated environment. Each treatment session is 20 minutes, during which their attention will be maintained using a software game.
Gender:
ALL
Ages:
Between 7 years and 12 years
Trial Updated:
09/17/2024
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: ADHD
Register for Updates
Phase 2 Study of EDG-5506 in Children and Adolescents with Duchenne Muscular Dystrophy Previously Treated with Gene Therapy (FOX)
NCT06100887
Recruiting
The FOX study is a 2-part, multicenter, Phase 2 study of safety, pharmacokinetics, and biomarkers in children and adolescents with Duchenne muscular dystrophy previously treated with gene therapy including a randomized, double-blind, placebo-controlled Part A, followed by an open-label part B.
Gender:
MALE
Ages:
Between 6 years and 17 years
Trial Updated:
09/17/2024
Locations: University of Massachusetts Memorial Medical Center, Worcester, Massachusetts
Conditions: Duchenne Muscular Dystrophy
Register for Updates
Brentuximab Vedotin and Nivolumab for the Treatment of Patients with Relapsed/refractory Classical Hodgkin Lymphoma
NCT04561206
Recruiting
This phase II trial investigates how well brentuximab vedotin and nivolumab work in treating patients with classical Hodgkin lymphoma that has come back after initial treatment (relapsed) or has not responded to initial treatment (refractory). Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. Nivolumab is an antibody that enhances the immune sys... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/17/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Relapsed Classic Hodgkin Lymphoma
Register for Updates
Abemaciclib and Endocrine Therapy in Older Patients with Breast Cancer.
NCT04305834
Recruiting
This phase IIa trial studies the side effects of abemaciclib monotherapy in treating patients age 70 years and older with hormone receptor positive, HER2 negative breast cancer that has spread to other places in the body.
Gender:
ALL
Ages:
70 years and above
Trial Updated:
09/17/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Carcinoma, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
Register for Updates
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
NCT04251052
Recruiting
This clinical trial evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries. This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk... Read More
Gender:
FEMALE
Ages:
Between 35 years and 50 years
Trial Updated:
09/17/2024
Locations: Baystate Medical Center, Springfield, Massachusetts
Conditions: Ovarian Carcinoma
Register for Updates
Reminder-cue Scanning Training for Homonymous Visual Field Loss
NCT06136169
Recruiting
This study will evaluate a new approach to training people with visual field loss to scan when driving
Gender:
ALL
Ages:
16 years and above
Trial Updated:
09/16/2024
Locations: Schepens Eye Research Institute of Mass Eye and Ear, Boston, Massachusetts
Conditions: Homonymous Hemianopia, Homonymous Quadrantanopia
Register for Updates
CRICKET: Critical Events in Anaesthetised Kids Undergoing Tracheal Intubation
NCT05804188
Recruiting
The investigators' overall objective is to assess the incidence of critical events related to tracheal intubation at all international study sites. Furthermore, the study will investigate the used intubation techniques and identify possible improvement measures to increase patient safety.
Gender:
ALL
Ages:
16 years and below
Trial Updated:
09/16/2024
Locations: Department of Anesthesiology, Critical Care and Pain Medicine, Boston, Massachusetts
Conditions: Intubation Complication, Adverse Events
Register for Updates
Ventilatory and Perfusion Abnormalities in Individuals with Post-Acute Sequelae of SARS-CoV-2 Infection
NCT05866952
Recruiting
Prospective cohort study to evaluate the utility of quantitative CT analysis to assess ventilation and perfusion defects in patients with Post-acute Sequelae of SARS-CoV-2 (PASC) and functional limitations
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
09/13/2024
Locations: Tufts Medical Center, Boston, Massachusetts
Conditions: Post-Acute COVID-19, Post COVID-19 Condition, Post Viral Fatigue, Dyspnea
Register for Updates
Study of SGR-1505 in Mature B-Cell Neoplasms
NCT05544019
Recruiting
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/13/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia, MALT Lymphoma, Follicular Lymphoma, Pediatric-Type Follicular Lymphoma, IRF4 Gene Rearrangement, EBV-Positive DLBCL, Nos, Burkitt Lymphoma, Plasmablastic Lymphoma, High-grade B-cell Lymphoma, Primary Cutaneous Follicle Center Lymphoma, Primary Effusion Lymphoma, Mantle Cell Lymphoma, DLBCL Germinal Center B-Cell Type, Primary Mediastinal Large B Cell Lymphoma, T-Cell/Histiocyte Rich Lymphoma, ALK-Positive Large B-Cell Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Splenic Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, Nodal Marginal Zone Lymphoma, HHV8-Positive DLBCL, Nos, Lymphoplasmacytic Lymphoma, Duodenal-Type Follicular Lymphoma
Register for Updates
Sequential Allocation Study of Music Duration
NCT04909736
Recruiting
The investigators are interested in studying the effects of varying lengths of musical exposure on patient anxiety and stress levels.
Gender:
FEMALE
Ages:
Between 18 years and 50 years
Trial Updated:
09/13/2024
Locations: Tufts Medical Center, Boston, Massachusetts
Conditions: Anxiety, Patient Satisfaction, Music Exposure
Register for Updates
A Study of Participants With Cerebral Adrenoleukodystrophy (CALD) Treated With Elivaldogene Autotemcel
NCT06224413
Recruiting
The main aim of this study is to assess and describe the safety outcomes, including newly diagnosed malignancies, of patients with CALD treated with eli-cel in the post-marketing setting (tradename Skysona) and to describe major functional disability (MFD)-free survival over time in participants with more advanced early active CALD. All enrolled participants with CALD treated with eli-cel in the post-marketing setting will be followed in this study for 15 years. No investigational drug product w... Read More
Gender:
MALE
Ages:
All
Trial Updated:
09/12/2024
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Cerebral Adrenoleukodystrophy (CALD)
Register for Updates